Pfizer Global Medical Grants & Partnerships is pleased to announce the latest grant opportunity with colleagues focused on Increasing Awareness & Understanding of Emerging Hemophilia Treatment ...

3SBio, along with its subsidiaries Shenyang Sunshine Pharmaceutical and 3S Guojian Pharmaceutical (Shanghai), will grant Pfizer exclusive global rights to SSGJ-707 outside of China. Pfizer retains the ...

Pfizer has entered into an exclusive global licensing agreement with 3SBio to develop, manufacture, and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF pathways. The therapy is ...

Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer ... contribute to a stable global vaccine supply, and achieve ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 ...

He will also cover business analytics, global commercial operations and patient and health impact, among others. Pfizer’s Consumer Healthcare business will also report to Young. New CEO Bourla ...

The drug “dovetails well” with Pfizer’s stockpile of antibody-drug conjugates “and adds another important pipeline candidate to [its] oncology portfolio,” wrote Leerink Partners analyst David Risinger ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma ... that U.S. biotech is ceding its innovation crown to the region. The global trade war ...

Priovant owns commercial rights in the US and Japan, with Pfizer keeping rights elsewhere. The partners say that the drug is a potential first-in-class therapy that could offer improved efficacy ...